Stipple Bio

Cambridge, MA · Founded 2021 · CIK 0001932776 · Biotech · Private

Platform for identifying and targeting tumor-specific cell surface proteins to develop precision oncology medicines

stipple.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$87M
3 Form D · Apr 2026
6 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$11,975,000
Private capital raisedForm D · SEC$9,476,070
Private capital raisedForm D · SEC$65,130,013
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2847Cardurion Pharmaceuticals—$350M
2848DIGITAL NANOGENETICS, LLC——
2849RETINAL SOLUTIONS LLC——
2850Stipple Bio—$87M
2851PPI PHARMACEUTICALS, LLC——
2852YOLO IMMUNE INC——
2853EMPHYMAB BIOTECH, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • Vineeta AgarwalaDirector
  • Derek DiRoccoDirector
  • Owen HughesDirector
  • Jeffrey LandauDirector · Executive Officer
  • Aaron RingDirector · Executive Officer
  • Thilo SchroederDirector
  • Greg VerdineDirector
  • Antoine YverDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.